Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis

por Meier, Julia C, Haendler, Bernard, Seidel, Henrik, Groth, Philip, Adams, Robert, Ziegelbauer, Karl, Kreft, Bertolt, Beckmann, Georg, Sommer, Anette, Kopitz, Charlotte
Publicado 2015

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models

por Quanz, Maria, Hagemann, Urs B., Zitzmann-Kolbe, Sabine, Stelte-Ludwig, Beatrix, Golfier, Sven, Elbi, Cem, Mumberg, Dominik, Ziegelbauer, Karl, Schatz, Christoph A.
Publicado 2018

In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients

por Kuboki, Yasutoshi, Schatz, Christoph A., Koechert, Karl, Schubert, Sabine, Feng, Janine, Wittemer-Rump, Sabine, Ziegelbauer, Karl, Krahn, Thomas, Nagatsuma, Akiko Kawano, Ochiai, Atsushi
Publicado 2017

Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI

por Georgi, Benjamin, Mielke, Johanna, Chaffin, Mark, Khera, Amit V., Gelis, Lian, Mundl, Hardi, van Giezen, J.J.J., Ellinor, Patrick, Kathiresan, Sekar, Ziegelbauer, Karl, Freitag, Daniel F.
Publicado 2019

BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I

por Ellinghaus, Peter, Heisler, Iring, Unterschemmann, Kerstin, Haerter, Michael, Beck, Hartmut, Greschat, Susanne, Ehrmann, Alexander, Summer, Holger, Flamme, Ingo, Oehme, Felix, Thierauch, Karlheinz, Michels, Martin, Hess-Stumpp, Holger, Ziegelbauer, Karl
Publicado 2013

Synergistic Effect of a Mesothelin-Targeted (227)Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models

por Wickstroem, Katrine, Hagemann, Urs B., Cruciani, Véronique, Wengner, Antje M., Kristian, Alexander, Ellingsen, Christine, Siemeister, Gerhard, Bjerke, Roger M., Karlsson, Jenny, Ryan, Olav B., Linden, Lars, Mumberg, Dominik, Ziegelbauer, Karl, Cuthbertson, Alan S.
Publicado 2019

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

por Grünewald, Sylvia, Politz, Oliver, Bender, Sebastian, Héroult, Mélanie, Lustig, Klemens, Thuss, Uwe, Kneip, Christoph, Kopitz, Charlotte, Zopf, Dieter, Collin, Marie‐Pierre, Boemer, Ulf, Ince, Stuart, Ellinghaus, Peter, Mumberg, Dominik, Hess‐Stumpp, Holger, Ziegelbauer, Karl
Publicado 2019

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

por Lücking, Ulrich, Scholz, Arne, Lienau, Philip, Siemeister, Gerhard, Kosemund, Dirk, Bohlmann, Rolf, Briem, Hans, Terebesi, Ildiko, Meyer, Kirstin, Prelle, Katja, Denner, Karsten, Bömer, Ulf, Schäfer, Martina, Eis, Knut, Valencia, Ray, Ince, Stuart, von Nussbaum, Franz, Mumberg, Dominik, Ziegelbauer, Karl, Klebl, Bert, Choidas, Axel, Nussbaumer, Peter, Baumann, Matthias, Schultz‐Fademrecht, Carsten, Rühter, Gerd, Eickhoff, Jan, Brands, Michael
Publicado 2017